Blood & Blood Products

The regulation of blood and blood products in Kenya is a critical aspect of public health, overseen primarily by the Pharmacy and Poisons Board (PPB) as the national medicines regulatory authority, alongside the operational functions of the Kenya National Blood Transfusion Service (KNBTS). This article examines the evolving legal and regulatory framework governing these essential medical resources. It highlights the PPB's mandate under the Pharmacy and Poisons Act (Cap 244) for licensing, marketing authorization, and quality assurance of blood-derived products, and the KNBTS's role in collection, testing, and distribution. Recent legislative developments, including the proposed Kenya Blood, Cells, Tissues and Organs Bill, 2025, signal a move towards a more integrated and robust regulatory and operational structure, aiming to enhance the safety, quality, and availability of blood and blood products across the country.

Blood and blood products are indispensable components of modern healthcare, vital for emergency medicine, surgical procedures, and the management of various chronic conditions. Ensuring their safety, efficacy, and adequate supply is a paramount public health responsibility. In Kenya, this critical oversight falls under a multi-faceted regulatory and operational framework that has seen significant evolution in recent years, reflecting a commitment to international best practices and national health priorities. The Pharmacy and Poisons Board (PPB), as Kenya's national medicines regulatory authority, plays a pivotal role in this ecosystem, particularly concerning the quality and market authorization of blood-derived medicinal products.

This article aims to provide legal professionals with a comprehensive understanding of the current regulatory landscape for blood and blood products in Kenya. It will delve into the statutory mandates of key institutions, the existing guidelines, and the ongoing legislative reforms designed to strengthen the sector. The dynamic nature of this regulatory environment necessitates continuous vigilance from practitioners involved in healthcare provision, pharmaceutical supply chains, and medical legal advisory roles, as compliance requirements are subject to change and enhancement.

The core thesis of this article is that while Kenya has established foundational legal instruments and institutions for regulating blood and blood products, the system is undergoing significant reforms to consolidate oversight, enhance quality assurance, and ensure sustainable supply. These reforms, particularly the proposed establishment of a unified Blood and Transplant Authority, are set to redefine compliance obligations and operational standards for all stakeholders.

The regulatory foundation for medical products and health technologies in Kenya is primarily laid out in the Pharmacy and Poisons Act (Cap 244) of the Laws of Kenya. This Act established the Pharmacy and Poisons Board (PPB) in 1957, mandating it to regulate the practice of pharmacy and the manufacture, trade, import, export, distribution, and use of drugs, poisons, and related health technologies. The PPB's comprehensive mandate extends to ensuring the safety, efficacy, and quality of pharmaceutical products, including biological therapeutics which encompass products derived from human blood and plasma.

Complementing the PPB's regulatory role is the Kenya National Blood Transfusion Service (KNBTS), established in 2000 within the Ministry of Health. The KNBTS is tasked with the crucial operational mandate of collecting, testing, processing, and distributing blood and blood products to all transfusing hospitals across Kenya. While KNBTS has been instrumental in managing the national blood supply, its statutory basis has historically been less defined, operating as a division within the Ministry of Health. This structural arrangement has prompted calls for dedicated legislation to formalize its powers and functions.

The Health Act, No. 21 of 2017, marked a significant step towards a more robust framework. Section 85 of the Health Act specifically calls for the establishment of the Kenya National Blood Transfusion Service through an Act of Parliament, outlining its mandate to develop a comprehensive and coordinated national blood service based on voluntary non-remunerated donations. This provision underscored the need for a dedicated legal instrument to govern blood and blood products, separate from the broader regulation of medicines, while acknowledging the interconnectedness with organ and tissue transplantation, as addressed in Sections 80-84 of the same Act.

The regulatory landscape for blood and blood products in Kenya is characterized by a dual approach, with the PPB focusing on product quality and market authorization, and the KNBTS managing the operational aspects of blood supply. The PPB, through its Blood and Blood Products Division, is responsible for regulating the licensure of blood, blood components, and granting marketing authorization for plasma-derived medicinal products and other human-derived products. This includes rigorous evaluation and approval processes for imported biological therapeutics, with the Pharmacy and Poisons (Amendment) Rules, 2022, requiring batch evaluation and approval by the Board before release into the market or for export.

Despite the KNBTS's vital role since its establishment in 2000, it has operated without a specific enabling statute, leading to challenges in funding and a clear legal framework for its superintendence and regulation. This gap has been a key driver for legislative reform. The Kenya National Blood Transfusion Service Bill, 2020, sought to establish KNBTS as a body corporate, defining its functions, powers, and providing for the regulation of blood donation, testing, processing, and quality control. This Bill also proposed specific offences and penalties for illegal dealing in blood and blood products, addressing a critical vulnerability in the system.

More recently, the legislative efforts have evolved towards a more integrated approach, as evidenced by the proposed Kenya Blood, Cells, Tissues and Organs Bill, 2025. This Bill aims to establish the Kenya Blood and Transplant Authority, which would succeed the Kenya Tissue and Transplant Authority (established under Legal Notice No. 142 of 2022). The new Authority is envisioned to coordinate blood donation, cell, tissue, and organ donation and transplantation, and to provide for the licensing and certification of transfusing facilities, transplant facilities, and retrieval facilities. This signifies a strategic shift towards a unified regulatory and oversight body for all human-derived medical products, aligning with international best practices that emphasize comprehensive quality management systems and traceability.

Furthermore, the Ministry of Health, in collaboration with the Kenya Blood Transfusion and Transplant Service, has developed the Kenya National Standards for Blood Transfusion Services (2nd Edition, 2022) and the Kenya Policy on Donation, Transfusion and Transplant of Human Derived Medical Products. These documents provide detailed guidelines on blood donor management, collection, testing, preparation, and administration, aiming to ensure safety and quality throughout the transfusion chain. It is also important to note that Kenya does not export donated human blood or blood components for manufacturing abroad; rather, plasma-derived blood products used domestically are imported from internationally accredited manufacturers, with KEMSA playing a role in their procurement and distribution.

The ongoing reforms address critical aspects such as the prohibition of the sale of blood, organs, or tissue, as stipulated in the proposed 2025 Bill, reinforcing the ethical framework of voluntary, non-remunerated donation. The establishment of a national blood and transplant reference laboratory and an Appeals Tribunal under the proposed Authority further strengthens the quality assurance and dispute resolution mechanisms within the sector.

The regulation of blood and blood products in Kenya is a dynamic and evolving field, reflecting the country's commitment to safeguarding public health and ensuring access to safe and high-quality medical resources. Practising attorneys and legal professionals must recognize the dual regulatory roles of the Pharmacy and Poisons Board (PPB) in product authorization and quality control, and the operational responsibilities of the Kenya National Blood Transfusion Service (KNBTS) in managing the national blood supply. The recent and ongoing legislative developments, particularly the proposed Kenya Blood, Cells, Tissues and Organs Bill, 2025, are poised to significantly reshape the legal and institutional framework, consolidating oversight under a new Kenya Blood and Transplant Authority.

For practitioners, this evolving landscape necessitates a thorough understanding of the Pharmacy and Poisons Act (Cap 244), the Health Act, 2017, and the specific national standards and policies governing blood transfusion services. Compliance with licensing requirements, marketing authorization procedures for blood-derived products, and adherence to quality management systems will remain paramount. Furthermore, staying abreast of the progress of the proposed legislation is crucial, as it will introduce new certification requirements for facilities, establish an appeals mechanism, and reinforce prohibitions against illegal dealing in blood and human tissues. The emphasis on a robust, transparent, and ethical framework underscores the need for continuous legal diligence and advisory support within Kenya's healthcare sector.